Stragen
Ronak Faraee is an experienced sales and marketing professional with a strong background in the pharmaceutical industry. Currently serving as Sales and Marketing Director at Live Anahita Pharmed since March 2017, Ronak previously held the role of Sales and Marketing Manager at Stragen Pharma SA from May 2013. Ronak's career includes experience as a Sales Manager at Bayer HealthCare from March 2010 to March 2014, where responsibilities included training a team of medical representatives and developing sales strategies. Earlier positions include Medical Representative at Bayer HealthCare from September 2006 to September 2009, focusing on field visits to gynecology practitioners. Ronak holds a DBA in Marketing and Strategy from Tehran Management Faculty, a Master’s in Obstetrics and Gynecology from Shahid Beheshti University, and an Executive MBA in Business Administration and Management from Tehran Management Faculty.
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.